What Organon & Co. told the SEC could break it.

China (a significant share of Organon's sales) runs volume-based procurement (VBP) and URPS programs; VBP regularly cuts affected-product prices by over 50%, pressuring Organon's China business.

“China has made reduction of costs and provision of affordable pharmaceutical products to patients a key priority and has implemented reimbursement and procurement programs to achieve these goals, such as VBP and URPS. For example, the VBP program regularly reduces the prices for affected products by over 50%.”

The IRA allows Medicare to set a 'Maximum Fair Price' for certain Part D/Part B drugs beginning 2028 and eliminated the Medicaid rebate cap, pressuring U.S. pricing for Organon's products.

“In addition, the Inflation Reduction Act of 2022 (“IRA”), among other things, allows Medicare to establish a “Maximum Fair Price” for certain pharmaceutical drug and biological products covered under Medicare Part D and Part B in 2028.”

Following an Audit Committee investigation into Nexplanon sales to certain U.S. wholesalers, the SEC opened an investigation; Organon ceased the identified sales practices (a $15M FY2025 sales impact) and is cooperating.

“The SEC subsequently opened an investigation into these matters, and the Company intends to cooperate with any inquiries from the SEC or any other regulatory authorities.”

A number of Organon's materials/components are sole-sourced, some critical to women's health and general medicines; notably it relies heavily on one supplier for formulation/packaging as its gateway to sales in both Japan and China.

“In particular, we rely heavily on one supplier for formulation and/or packaging as our gateway to sales in both Japan and China.”